-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $129

Benzinga·06/05/2025 17:39:50
Listen to the news
Morgan Stanley analyst Judah Frommer maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $102 to $129.